SCHEMBL2931394

SCHEMBL2931394

CC(C)(C)OC(=O)NCCC[C@H](N)C(=O)NCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 1/20 0.52
CA1 P00915 3/20 0.52
CA2 P00918 2/20 0.52
CTSK P43235 4/20 0.51
MAPT P10636 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MMP1 P03956 1/20 0.48
MMP3 P08254 1/20 0.48
MMP9 P14780 1/20 0.48
CYP3A4 P08684 1/20 0.47
IDO1 P14902 1/20 0.47
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
ATM Q13315 1/20 0.46
SIGMAR1 Q99720 1/20 0.45
ANPEP P15144 1/20 0.45
BACE1 P56817 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3584002 0.93 CTSK (0.50) MEN1KMT2AGAACA1CA2
SCHEMBL2921238 0.93 CTSK (0.50) MEN1KMT2AGAACA1CA2
SCHEMBL2928288 0.87 CTSL (0.48) MEN1KMT2AGAACA1CA2
SCHEMBL24627782 0.87 MEN1 (0.53) MEN1KMT2AGAACA1CA2
SCHEMBL17537309 0.85 CA1 (0.56) MEN1KMT2AGAACA1CA2
SCHEMBL17133705 0.85 CA1 (0.56) MEN1KMT2AGAACA1CA2
SCHEMBL26268412 0.85 ATM (0.52) KMT2ACA1CA2CTSKIDO1
SCHEMBL17133738 0.85 CA1 (0.49) MEN1KMT2ACA1CA2MAPT
SCHEMBL17537311 0.85 CA1 (0.49) MEN1KMT2ACA1CA2MAPT
SCHEMBL2928021 0.84 MEN1 (0.53) MEN1KMT2AGAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118681025-A Hydrotalcite material loaded with PAD4 inhibitor and preparation method and application thereof 首都医科大学 2024-09-24 CN disclosed
WO-2022148457-A1 SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF HELIOS HUAMING BIOPHARMA CO., LTD. (CN) 2022-07-14 WO disclosed
EP-1675824-B1 SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS WURSTER SIEGFRIED (FI) 2010-09-29 EP disclosed
US-7741362-B2 Somatostatin receptor 1 and/or 4 selective agonists and antagonists SIEGFRIED WURSTER (FI) 2010-06-22 US disclosed
US-20100004339-A1 Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists OY JUVANTIA PHARMA LTD. (FI) 2010-01-07 US disclosed
US-20070129422-A1 Somatostatin receptor 1 and/or 4 selective agonists and antagonists OY JUVANTIA PHARMA LTD (FI) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129422-A1 Somatostatin receptor 1 and/or 4 selective agonists and antagonists SSTR4, SSTR1, SSTR3 MEN1 822/4885KMT2A 2112/4885GAA 2847/4885
US-20100004339-A1 Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists SSTR4, SSTR1, SSTR3 MEN1 822/4885KMT2A 2112/4885GAA 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.